Bridgefront Capital LLC Invests $667,000 in Globus Medical, Inc. $GMED

Bridgefront Capital LLC acquired a new stake in Globus Medical, Inc. (NYSE:GMED) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 11,642 shares of the medical device company’s stock, valued at approximately $667,000.

Several other institutional investors and hedge funds also recently made changes to their positions in GMED. California Public Employees Retirement System lifted its stake in Globus Medical by 7.0% in the third quarter. California Public Employees Retirement System now owns 206,913 shares of the medical device company’s stock worth $11,850,000 after purchasing an additional 13,549 shares during the last quarter. Bank of America Corp DE boosted its position in Globus Medical by 10.0% during the third quarter. Bank of America Corp DE now owns 709,633 shares of the medical device company’s stock valued at $40,641,000 after buying an additional 64,265 shares during the period. Braidwell LP grew its stake in shares of Globus Medical by 101.5% during the third quarter. Braidwell LP now owns 498,000 shares of the medical device company’s stock valued at $28,520,000 after buying an additional 250,800 shares during the last quarter. ArrowMark Colorado Holdings LLC increased its holdings in shares of Globus Medical by 25.1% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,202,488 shares of the medical device company’s stock worth $68,866,000 after buying an additional 241,236 shares during the period. Finally, Alliancebernstein L.P. increased its holdings in shares of Globus Medical by 1,303.9% in the third quarter. Alliancebernstein L.P. now owns 2,055,183 shares of the medical device company’s stock worth $117,700,000 after buying an additional 1,908,795 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical News Summary

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Insider Transactions at Globus Medical

In related news, Director Leslie V. Norwalk sold 2,000 shares of the firm’s stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $101.10, for a total value of $202,200.00. Following the completion of the sale, the director owned 10,419 shares of the company’s stock, valued at $1,053,360.90. This trade represents a 16.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Kelly Huller sold 20,000 shares of Globus Medical stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total transaction of $1,890,000.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 35,594 shares of company stock worth $3,332,253. 18.54% of the stock is currently owned by insiders.

Globus Medical Trading Up 0.4%

Globus Medical stock opened at $84.81 on Monday. The firm has a 50-day moving average of $90.71 and a 200-day moving average of $78.49. The firm has a market cap of $11.47 billion, a P/E ratio of 21.52, a P/E/G ratio of 1.99 and a beta of 1.05. Globus Medical, Inc. has a 1-year low of $51.79 and a 1-year high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.22. The company had revenue of $826.42 million for the quarter, compared to the consensus estimate of $803.29 million. Globus Medical had a return on equity of 12.57% and a net margin of 18.30%.Globus Medical’s revenue was up 25.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.84 EPS. Research analysts forecast that Globus Medical, Inc. will post 3.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Canaccord Genuity Group boosted their target price on Globus Medical from $105.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Wells Fargo & Company boosted their price objective on Globus Medical from $98.00 to $104.00 and gave the company an “overweight” rating in a research report on Thursday, February 26th. TD Cowen raised Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, BTIG Research restated a “neutral” rating on shares of Globus Medical in a report on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Globus Medical presently has a consensus rating of “Moderate Buy” and an average price target of $104.36.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.